A new ganoderic acid from Ganoderma lucidum mycelia and its stability

Area of Science:

• Natural Product Chemistry
• Medicinal Chemistry
• Mycology

Background:

• Ganoderma lucidum (Reishi mushroom) is a source of bioactive compounds called ganoderic acids (GAs).
• Understanding the chemical properties and biological activities of GAs is crucial for their pharmaceutical applications.
• Previous studies have identified various GAs, but their stability and degradation pathways require further investigation.

Purpose of the Study:

• To isolate and characterize new and known ganoderic acids from Ganoderma lucidum mycelia.
• To evaluate the chemical stability of a newly identified ganoderic acid.
• To assess the in vitro cytotoxic activities of the isolated compounds against specific tumor cell lines.

Main Methods:

• Isolation and structural elucidation of ganoderic acids using extensive spectroscopic data (HRMS, IR, UV, 1D and 2D NMR).
• Stability assessment of the new ganoderic acid in various solvents.
• Proposal of a degradation mechanism for the new ganoderic acid in methanol.
• In vitro cytotoxicity assays against 95D and HeLa tumor cell lines.

Main Results:

• A new ganoderic acid, 3α,22β-diacetoxy-7α-hydroxyl-5α-lanost-8,24E-dien-26-oic acid, was isolated and characterized, along with four known GAs.
• Compound 1 exhibited optimal stability in an aprotic environment, with a proposed acid-catalyzed degradation mechanism in methanol.
• All isolated compounds demonstrated in vitro cytotoxic activity, with IC(50) values ranging from 14.7 to 38.5 μM.

Conclusions:

• The study successfully identified and characterized a novel ganoderic acid from Ganoderma lucidum mycelia.
• Findings provide insights into the chemical stability of ganoderic acids, crucial for their handling and application.
• The demonstrated cytotoxic activities suggest potential therapeutic value for these compounds in cancer research.